INmune Bio, Inc. furnished an investor presentation as Exhibit 99.1 under Item 7.01 detailing its late-stage pipeline including CORDStrom for RDEB with Phase III data showing improvements in itch, pain, and organ systems, supported by patents through 2045 and planned regulatory submissions in 2025-2026. The presentation highlights mechanisms of action and path to commercial approval.
Key takeaways
Investor Presentation furnished as Exhibit 99.1 for use in presentations
CORDStrom Phase III MISSION EB trial data shows ISCOREB improvements in itch, pain, skin, eye, joint, mouth at 3 and 6 months vs placebo
CORDStrom patents with nominal coverage through 2045, eligible for PTE up to +5 years
Regulatory milestones: RPDD approved Dec 2024, ODD approved Jan 2025, MAA to MHRA/EMA Q3 2026, BLA to FDA Q4 2026
XPro1595 patents including US 11,365,229 B2 expiring 2033, eligible for Reference Biological Product Exclusivity ~12 years